2 小时on MSN
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new ...
Q4 2025 Management View CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a robust development case. Dhillon stated, "CBeyond ...
WebFX reports that brands can guard their reputation in the AI age by correcting misinformation, engaging communities, and updating content.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果